World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
58
Citations
32965
World Ranking
12875
National Ranking
5478

Overview

Michael Kalos is affiliated with Next Pillar Consulting in the United States and has contributed to research primarily within the fields of Medicine and Immunology and Microbiology. The scientist's work focuses strongly on Oncology and Immunology, with subfields including Biomedical Engineering, Molecular Biology, and Physiology.

The main topics in Michael Kalos's research include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Biomedical and Engineering Education
  • Angiogenesis and VEGF in Cancer
  • Biomedical Ethics and Regulation

Michael Kalos has published frequently in several venues, with notable contributions to:

  • Cytotherapy
  • Regular and Young Investigator Award Abstracts
  • Cancer Immunology Research
  • PLoS ONE
  • Molecular Cancer Therapeutics

Among recent papers, important publications include:

  • "Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity" (2020) published in Cancer Immunology Research
  • "Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity" (2020) published in Molecular Cancer Therapeutics
  • "Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models" (2022) published in PLoS ONE
  • "Accelerating the development of innovative cellular therapy products for the treatment of cancer" (2020) published in Cytotherapy
  • "Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products" (2024) published in Cytotherapy

Frequent co-authors in Michael Kalos's publications include Ivan Inigo, Ruslan D. Novosiadly, Aleksandra Vuchkovska, Helen Kotanides, and Carmine Carpenito.

Best Publications

  • Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

  • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

    Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

  • T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

  • Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

    Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

  • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  • Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

  • NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    Aaron P Rapoport;Edward A Stadtmauer;Gwendolyn K Binder-Scholl;Olga Goloubeva

  • Use of chimeric antigen receptor-modified t cells to treat cancer

    Carl H. June;Bruce L. Levine;David L. Porter;Michael D. Kalos

  • Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

    Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

  • Monoclonal TCR-redirected tumor cell killing

    Nathaniel Liddy;Giovanna Bossi;Katherine J. Adams;Anna Lissina

  • Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

    John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

  • Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

    Brian J. Cameron;Andrew B. Gerry;Joseph Dukes;Jane V. Harper

  • Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

    David T. Teachey;David T. Teachey;Susan R. Rheingold;Susan R. Rheingold;Shannon L. Maude;Shannon L. Maude;Gerhard Zugmaier

  • T cells expressing chimeric antigen receptors can cause anaphylaxis in humans

    Marcela V. Maus;Andrew R. Haas;Gregory L. Beatty;Steven M. Albelda

  • Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

    Michael C. Jensen;Leslie Popplewell;Laurence J. Cooper;David DiGiusto

  • Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

    Marco Ruella;David M. Barrett;Saad S. Kenderian;Olga Shestova

  • Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

    Michael Kalos;Carl H. June

  • Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

    Saar Gill;Sarah K. Tasian;Marco Ruella;Olga Shestova

  • RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

    David L. DiGiusto;Amrita Krishnan;Lijing Li;Haitang Li

  • USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT MALIGNANCIES

    June Carl H;Porter David L;Kalos Michael D;Milone Michael C

Frequent Co-Authors

Carl H. June
Carl H. June University of Pennsylvania
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
David L. Porter
David L. Porter University of Pennsylvania
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Bent K. Jakobsen
Bent K. Jakobsen Continuum Life Sciences
Michael C. Milone
Michael C. Milone University of Pennsylvania
Simon F. Lacey
Simon F. Lacey University of Pennsylvania
David M. Barrett
David M. Barrett Children's Hospital of Philadelphia
Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
David T. Teachey
David T. Teachey Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Biology or Biochemistry opens doors to a wide range of allied health careers. Many students are choosing flexible, accredited online programs to build specialized skills or begin new career journeys.

If you’re interested in medical imaging, the best online radiology tech programs offer affordable options to train as a radiologic technologist. For those passionate about nutrition science, dietitian masters programs can lead to advanced credentials and greater opportunities in healthcare settings.

Entry-level healthcare roles are also in high demand. You might consider online medical assisting classes, many of which offer financial aid. For current medical assistants aiming to further their careers, a cma to lpn bridge program online could be the next step, providing a path toward becoming a licensed practical nurse.

Each of these online pathways is designed to fit a variety of interests within health and life sciences, making it easier than ever to align your biology or biochemistry background with meaningful career options.

Best Scientists Citing Michael Kalos

Trending Scientists